A detailed guide to what the Ninth Circuit held, why Astra did not bar the case, how 340B penny pricing fits into the allegations, and what whistleblowers should know.

Quick Takeaways:

• A covered entity can pursue an FCA theory as a relator even though Section 340B has no private right of action.
• The key distinction is between enforcing Section 340B directly and seeking FCA damages for fraud on the government.
• Astra still matters, but it does not automatically defeat a 340B-based FCA complaint.
• The Ninth Circuit also held that Adventist plausibly pleaded falsity, including as to pre-January 1, 2019 allegations.
• The decision is binding in the Ninth Circuit. Other courts may find it persuasive, but they are not required to follow it.

On March 17, 2026, the Ninth Circuit issued a significant decision for healthcare fraud, pharmaceutical pricing, and whistleblower law. In United States ex rel. Adventist Health System of West v. AbbVie Inc., the court held that a 340B overcharge theory can support a False Claims Act case when the alleged misconduct is tied to false or inflated claims paid by the government.

Section 340B itself does not give covered entities a private right of action to sue manufacturers for overcharges. But the Ninth Circuit held that this does not automatically bar a qui tam case under the False Claims Act when the relator is seeking relief for government losses rather than trying to recover its own overcharges.

The opinion does not mean every 340B dispute is now a winning FCA case. It does mean that defendants can no longer assume Astra ends the analysis whenever a 340B-covered entity is the relator. The harder question is now the one that usually matters in FCA litigation: did the alleged pricing conduct cause the government to pay money it should not have paid or did it cause the government to pay more money than it should have?

What Happened in Adventist Health v. Abbvie?

Adventist, a nonprofit health system and 340B covered entity, alleged that several manufacturers charged unlawfully inflated prices for covered outpatient drugs. The theory was not limited to direct injury to Adventist or other covered entities. According to the complaint, the alleged overcharges moved into government payments in several ways.

The Ninth Circuit described three alleged pathways. First, Adventist alleged that Medicaid paid covered entities based on inflated acquisition costs. Second, it alleged that critical access hospitals billed Medicare at 101 percent of drug costs, which meant inflated costs translated into inflated Medicare payments. Third, it alleged that government-funded prisons and clinics paid the inflated prices directly.

Adventist also pointed to a sudden drop in certain prices to $0.01 per unit after January 2019. It alleged that this sharp change was not the product of market forces or a new statutory requirement, but evidence that the manufacturers had long been pricing above the lawful ceiling and then corrected course once enforcement risk increased.

What Is the 340B Program, and What Is ‘Penny Pricing’?

The 340B Drug Pricing Program requires participating manufacturers to provide covered outpatient drugs to eligible covered entities at or below a statutory ceiling price. HRSA explains the program in practical terms: it is meant to help covered entities stretch scarce federal resources and provide more services to eligible patients.

The ceiling price is based on a statutory formula. HRSA also states that when the 340B ceiling price calculation produces an amount below $0.01, the ceiling price is $0.01. That is the so-called penny pricing rule.

HRSA’s current FAQ states that the 340B Ceiling Price and Civil Monetary Penalties regulation took effect on January 1, 2019, and that the regulation replaced the agency’s earlier 2011 penny-pricing policy release. The Ninth Circuit nevertheless held that Adventist plausibly alleged pre-2019 falsity because, as pleaded, the statute’s text and preexisting guidance already made clear that manufacturers could not charge more than $0.01 when the formula yielded a negative ceiling price.

Why the District Court Dismissed the Case

The district court treated Adventist’s complaint as an improper attempt to do indirectly what covered entities cannot do directly under Section 340B. That reasoning leaned heavily on Astra USA, Inc. v. Santa Clara County, the Supreme Court’s 2011 decision holding that covered entities may not sue manufacturers as third-party beneficiaries of pharmaceutical pricing agreements in order to recover overcharges.

Under Astra, a covered entity that claims it was overcharged does not get a direct private lawsuit for reimbursement. The statutory regime instead places administration and enforcement of the program with HHS and HRSA, including the Administrative Dispute Resolution process for direct pricing disputes.

The district court extended that logic into the FCA context. In effect, it concluded that a covered entity should not be able to repackage a 340B pricing dispute as a whistleblower case and sidestep the remedial structure Congress created.

Why the Ninth Circuit Reversed

The Ninth Circuit disagreed for three separate reasons, and each one matters for future 340B whistleblower cases.

First, the court said the FCA is a free-standing statute. Adventist was not suing under Section 340B. It was suing under the FCA on behalf of the government. The absence of a private right of action under Section 340B was therefore immaterial to the source of Adventist’s cause of action.

Second, the court held that Adventist was not ‘in essence’ trying to enforce Section 340B. That was the key difference from Astra. In Astra, the plaintiff sought compensatory relief for overcharges suffered by covered entities. In Adventist, the relator sought FCA damages for false claims and government loss. The court repeatedly described that as a prototypical FCA theory rather than a disguised 340B contract suit.

Third, the panel rejected the idea that Section 340B implicitly displaced the FCA. Congress knows how to create exceptions to the FCA. The court found no statutory basis to create a judge-made exception for 340B-related fraud claims that allegedly caused financial loss to the government.

Why Sutton Mattered

One of the most useful parts of the opinion for future relators is the court’s reliance on United States ex rel. Sutton v. Double Day Office Services, Inc. Sutton involved another federal statute that lacked a private right of action. Even so, the Ninth Circuit had already held that the absence of a direct statutory remedy did not block an FCA case where the defendant allegedly caused false claims for payment.

That analogy gave the Adventist panel a clean doctrinal path. The court emphasized that an FCA plaintiff sues in the name of the United States, not in a personal capacity. So the fact that the relator also happens to be a covered entity without a direct Section 340B cause of action does not defeat the FCA theory by itself.

This part of the opinion is important because it gives future plaintiffs more than a case-specific result. It gives them a framework. If the theory is really about fraud on the government, and not just a dressed-up overcharge dispute, the lack of a direct cause of action in the underlying statute may not be fatal.

How the Court Handled Falsity and the Pre-2019 Issue

The manufacturers argued that even if Astra did not bar the case, the complaint still failed because the alleged claims before January 1, 2019 could not be false. Their argument was that HRSA’s final ceiling-price and civil-monetary-penalties rule did not become effective until that date.

The Ninth Circuit rejected that argument at the pleading stage. It held that Adventist plausibly alleged that the statutory formula itself did not authorize pricing above $0.01 where the formula yielded a negative ceiling price. The court also noted HRSA’s formal 2011 penny-pricing guidance. In other words, the 2019 effective date did not automatically wipe out earlier allegations.

This was not a final merits ruling. The panel did not decide that the manufacturers actually violated the law, only that the complaint plausibly alleged falsity and could move past dismissal.

Why This Decision Matters for 340B Whistleblower Cases

For would-be whistleblowers, the decision matters because it narrows a common defense position. Before Adventist, defendants could argue that any 340B overcharge claim by a covered entity was dead on arrival because Section 340B lacks a private right of action and Astra closed the door. That argument is now much weaker in the Ninth Circuit when the complaint is built around government overpayment.

The opinion also shows what a viable 340B FCA narrative looks like. The relator needs more than a pricing disagreement. The complaint should explain how the pricing conduct moved into specific government payments, why those payments were inflated or false, and why the defendant allegedly knew the pricing was unlawful.

That is why 340B whistleblower cases often depend on operational detail. The strongest cases usually involve people who understand pricing, government reimbursement, chargebacks, finance, gross-to-net calculations, market access, or 340B program administration rather than people who only suspect that something was wrong.

What Evidence May Matter in a 340B Overcharge Whistleblower Case

• internal pricing emails, spreadsheets, or approvals discussing ceiling-price calculations, AMP, URA, or penny-pricing exposure
• chargeback, contract, and rebate data showing what covered entities were actually charged
• pricing changes around January 2019 or other compliance milestones
• reimbursement records showing how the inflated costs allegedly moved into Medicaid, Medicare, or other government payments
• communications with HRSA, auditors, outside consultants, or counsel regarding 340B pricing or correction efforts
• documents showing how the company described the issue internally, including whether it treated the conduct as a legal or compliance problem

What the Decision Did Not Decide

This is where many short competitor articles stop too early. Adventist is a major pleading-stage win, but it does not resolve the entire case.

The Ninth Circuit did not decide that the manufacturers actually overcharged anyone. It did not decide scienter on a developed record. It did not calculate damages. It did not hold that every Section 340B violation automatically creates FCA liability. And it did not decide whether other circuits will follow the same path.

That matters for readers searching terms like ‘can a 340B overcharge create FCA liability’ or ‘does Adventist Health v. AbbVie mean every 340B pricing dispute is fraud.’ The answer is no. The case opens a path. It does not eliminate the usual FCA battles over proof, causation, knowledge, and damages.

340B ADR Versus FCA: Why the Remedy Difference Matters

The remedy difference helped the Ninth Circuit separate Adventist from Astra. For a direct pricing dispute, the Section 340B ADR process can address reimbursement for overcharges or even termination of a manufacturer’s pricing agreement. That is a direct program-enforcement remedy.

An FCA case is different. The injury being asserted is injury to the government. The remedy is also different: statutory FCA damages and penalties tied to false claims paid with government funds. The relator may receive a share of any recovery, but the real party in interest is still the United States or the affected state governments.

That distinction is not just formal. It is the reason the court said Adventist was not doing an end-run around Astra. It was pursuing a different cause of action for a different injury and a different form of relief.

Frequently Asked Questions About 340B Overcharges and FCA Liability

Does Section 340B itself let covered entities sue manufacturers for overcharges? No. Astra remains the starting point on that issue. A direct suit for overcharge reimbursement is still not the same thing as an FCA case.

Can a covered entity ever act as a whistleblower in a 340B case? Yes. Adventist confirms that a covered entity may serve as a relator when it seeks relief on behalf of the government for false claims or fraudulent overpayments rather than reimbursement for its own overcharges.

Did the Ninth Circuit say the case was proven? No. The ruling was at the motion-to-dismiss stage. It only means the complaint stated a plausible claim and may proceed.

Does the case matter outside the Ninth Circuit? Yes, but in a limited way. The decision is binding in the Ninth Circuit and potentially persuasive elsewhere. Other circuits could agree, distinguish it, or go another direction until the issue develops further.

What is the best practical lesson from Adventist? Trace the money. In 340B pricing cases, the most important question is often how the alleged price inflation translated into a claim, reimbursement, or direct government payment.

Bottom Line

If you are asking whether 340B overcharges can support a False Claims Act case, the Ninth Circuit’s answer is yes when the alleged scheme caused the government to pay more than it should have paid. That is the central holding of Adventist Health v. AbbVie.

For whistleblowers, compliance professionals, and counsel evaluating a possible 340B drug pricing fraud case, the decision is important because it separates direct program enforcement from fraud-on-the-government theories. It also shows why details matter. The best cases are the ones that can connect pricing conduct, internal knowledge, and downstream government payment with precision.

If you are evaluating a potential 340B whistleblower claim, early legal analysis matters. The filing strategy, the evidence package, and the way the government-loss theory is framed can determine whether a case looks like a barred overcharge dispute or a viable FCA action.

Primary authorities and official sources

• United States ex rel. Adventist Health System of West v. AbbVie Inc., No. 24-2180 (9th Cir. Mar. 17, 2026).
• Astra USA, Inc. v. Santa Clara County, 563 U.S. 110 (2011).
• 42 U.S.C. § 256b.
• 31 U.S.C. §§ 3729-3730.
• HRSA, 340B Drug Pricing Program.
• HRSA FAQs, Manufacturer Compliance (effective date and penny-pricing questions).
• 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation, 83 Fed. Reg. 61563 (Nov. 30, 2018).

This article is drafted as an educational legal explainer, not legal advice. The facts and allegations discussed above.